Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011219 | 0.79 | CHRNB2 (0.47) | CHRNB2CHRNA4RECQLCHRNA7DRD2 | |
| SCHEMBL24316297 | 0.76 | PRCP (0.60) | CHRNB2CHRNA4RECQLCHRNA7SIGMAR1 | |
| SCHEMBL27919615 | 0.75 | CHRNB2 (0.43) | CHRNB2CHRNA4RECQLCHRNA7SIGMAR1 | |
| SCHEMBL24317436 | 0.75 | CHRNB2 (0.43) | CHRNB2CHRNA4RECQLCHRNA7SIGMAR1 | |
| SCHEMBL1641731 | 0.73 | PRCP (0.58) | RECQLPRCPGAA | |
| SCHEMBL31059287 | 0.73 | PRCP (0.58) | RECQLPRCPGAA | |
| SCHEMBL18795036 | 0.72 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNA7SIGMAR1FDPS | |
| Bromide SCHEMBL6103530 | 0.72 | PRCP (0.56) | RECQLDRD1PRCPGAA | |
| Methane SCHEMBL11849343 | 0.72 | PRCP (0.56) | RECQLPRCPGAA | |
| SCHEMBL3964346 | 0.69 | KDM1A (0.58) | RECQLPRCPGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | EVOTEC SE (DE) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | BDNF, OPRL1, GRIN2D | CHRNB2 84/4885CHRNA4 74/4885RECQL 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.